Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda
Journal of Antimicrobial Chemotherapy · 02.04.2025 · 80 (4) · 955-961
DOI: 10.1093/jac/dkaf018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 30.01.2025. Verfasst von Daniel Omoding und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of Health (NIH), NIMH NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechanism and lack of cross-resistance with other antiretroviral classes make lenacapavir a significant addition to HIV therapy. The clinical trials CALIBRATE and CAPELLA have demonstrated high viral suppression rates in both ART-naive individuals and individuals with MDR HIV-1. Lenacapavir-associated resistance mutations, such as M66I and Q67H, rarely seen as natural polymorphisms in lenacapavir-naive populations, are predominantly studied in subtype B HIV-1.
Objectives
Our study aimed to investigate the prevalence of lenacapavir resistance-associated mutations in HIV-1 subtypes A1 and D in a cohort of individuals living with HIV-1 from southwestern Uganda.
Methods
Utilizing plasma samples from ART-naive adults living in Uganda, HIV-1 Gag p24 (capsid) sequences were analysed for lenacapavir resistance mutations.
Results
Among 546 lenacapavir-naive participants, no major lenacapavir resistance-associated mutations were found. Minor mutations were present in 1.6% of participants, with T107A being the most common. Longitudinal data indicated the persistence of T107A for at least 3 years post-ART initiation in one participant. Phylogenetic analysis indicated individuals carrying T107A were found independently in distinct locations within the tree, suggesting that T107A might have arisen from multiple distinct base substitution events. Shannon entropy analysis showed high variability in certain capsid sites, but none overlapped with known lenacapavir resistance sites.
Conclusions
These findings suggest a low prevalence of naturally occurring lenacapavir resistance mutations in Uganda, supporting lenacapavir’s potential efficacy in this region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda.
- Institut Pasteur de Bangui, Bangui, Central African Republic.
- Department of Medicine, University of California, San Francisco, CA, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
- College of Health Sciences, VinUniversity, Hanoi, Vietnam.
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA.
ORCID-Profile: Daniel Omoding, Guinevere Q Lee
Förderung
- National Institute of Health (NIH)
- NIMH NIH HHS
- NIAID NIH HHS
Zitieren
APA
Omoding, D., Musinguzi, N., Boum, Y., Muzoora, C., Kigozi, S., Hunt, P. W., Martin, J. N., Bangsberg, D. R., Haberer, J. E., Siedner, M. J., McCluskey, S. M., & Lee, G. Q. (2025). Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda. Journal of Antimicrobial Chemotherapy, 80(4), 955-961. https://doi.org/10.1093/jac/dkaf018
Vancouver
Omoding D, Musinguzi N, Boum Y, Muzoora C, Kigozi S, Hunt PW, et al. Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda. Journal of Antimicrobial Chemotherapy. 2025;80(4):955-961. doi:10.1093/jac/dkaf018
BibTeX
@article{Omoding2025,
author = {Omoding, Daniel and Musinguzi, Nicholas and Boum, Yap and Muzoora, Conrad and Kigozi, Simone and Hunt, Peter W and Martin, Jeffrey N and Bangsberg, David R and Haberer, Jessica E and Siedner, Mark J and McCluskey, Suzanne M and Lee, Guinevere Q},
title = {Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {4},
pages = {955--961},
doi = {10.1093/jac/dkaf018}
}
EUVIMED